Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine for Cognitive Impairments in Schizophrenia
NCT07359209Completed
- Sponsor
- Tianjin Anding Hospital
- Start
- Jul 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of berberine in schizophrenia (2 arms), sponsored by Tianjin Anding Hospital. Primary endpoint: MATRICS Consensus Cognitive Battery Overall Composite Score at 12 weeks. Started Jul 2023; status: completed.
02
Drugs
berberine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07359209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07359209.